Functional genomics of the oxidative stress pathway

Current Hypertension Reviews

Volumn 3, Issue 3, 2007, Pages 156-165

  Delles, Christian ^a   Moreno, María U ^a   Padmanabhan, Sandosh ^a   Graham, Delyth ^a   McBride, Martin W ^a   Dominiczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Genomics; Glutathione S transferases; NADPH oxidase; Oxidative stress; Systems biology

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE M1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CONGENIC STRAIN; DNA SEQUENCE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE TECHNOLOGY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTENSION; MICROARRAY ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE TRAIT LOCUS; REVIEW; SEQUENCE ANALYSIS; SYSTEMS BIOLOGY;

EID: 34547890304     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207781386675     Document Type: Review

References (145)

1. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-5.
2. Ray R, Shah AM. NADPH oxidase and endothetial cell function. Clin Sci (Lond) 2005; 109: 217-26.
3. Miller AA, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: are they all bad? Antioxid Redox Signal 2006; 8:1113-20.
4. Opara EC. Oxidative stress. Dis Mon 2006; 52: 183-98.
5. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-52.
6. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-6.
7. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108: 2034-40.
8. Hamilton CA, Miller WH, Al-Benna S, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004; 106: 219-34.
9. Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101: 2206-12.
10. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 2001; 37:529-34.
11. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002;40:755-62.
12. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 20:281-6.
13. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002; 51: 1118-24.
14. Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, Utsumi H. Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res 2003; 37: 767-72.
15. Al-Benna S, Hamilton CA, McClure JD, et al. Low-density lipo-protein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 218-23.
16. Tarpey MM, Fridovich I. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 2001; 89: 224-36.
17. Hamilton CA, Groves S, Carswell HV, Brosnan MJ, Graham D, Dominiczak AF. Estrogen Treatment Enhances Nitric Oxide Bioavailability in Normotensive but not Hypertensive Rats. Am J Hypertens 2006; 19: 859-66.
18. Afanas'ev IB. Lucigenin chemiluminescence assay for superoxide detection. Circ Res 2001; 89: E46.
19. Zhao H, Kalivendi S, Zhang H, et al. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 2003; 34: 1359-68.
20. Zhao H, Joseph J, Fales HM, et al. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc Natl Acad Sci U S A. 2005; 102: 5727-32. Erratum in: Proc Natl Acad Sci U S A 2005; 102: 9086.
21. Fink B, Laude K, McCann L, Doughan A, Harrison DG, Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol 2004; 287: C895-902.
22. Fink B, Dikalov S, Bassenge E. A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo. Free Radic Biol Med 2000; 28: 121-8.
23. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003; 107: 1383-9.
24. Dikalov S, Fink B. ESR techniques for the detection of nitric oxide in vivo and in tissues. Methods Enzymol 2005; 396: 597-610.
25. Wyche KE, Wang SS, Griendling KK, et al. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004; 43: 1246-51.
26. Zalba G, Beloqui O, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25: 1452-7.
27. Fortuno A, San Jose G, Moreno MU, Beloqui O, Diez J, Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006; 55: 209-15.
28. McBride MW, Brosnan MJ, Mathers J, et al. Reduction of Gsun1 expression in the stroke-prone spontaneously hypertension rat contributes to increased oxidative stress. Hypertension 2005; 45: 786-92.
29. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The association between pre-hypertension status and oxidative stress markers related to atherosclerotic disease: The ATTICA study. Atherosclerosis 2006; in press. doi:10.1016/j.atherosclerosis.2006.04.030.
30. Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 2005; 10 Suppl 1: S24-9.
31. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-8.
32. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
33. Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349: 1605-13.
34. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8. Erratum in: Circulation 2003; 108: 500.
35. Schneider MP, Klingbeil AU, Delles C, Schmidt BM, John S, Schmieder RE. Vitamin C augments the renal response to L-arginine in smokers. Nephrol Dial Transplant 2003; 18: 1512-7.
36. Delles C, Schneider MP, Oehmer S, Fleischmann I, Fleischmann EF, Schmieder RE. Increased response of renal perfusian to the antioxidant vitamin C in type 2 diabetes. Nephrol Dial Transplant 2004; 19: 2513-8.
37. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35: 1289-93.
38. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37: 1351-8.
39. Wykretowicz A, Guzik P, Kasinowski R, et al. Augmentation index, pulse pressure amplification and superoxide anion production in patients with coronary artery disease. Int J Cardiol 2005; 99: 289-94.
40. Delles C, Zimmerli LU, McGrane DJ, et al. High-fidelity phenotyping of aortic compliance and vascular superoxide production unravels functional relationship between oxidative stress and vascular stiffness in humans. J Hypertans 2006;24 (suppl 4): S157 (abstract).
41. Wilkinson IB, Megson IL, MacCallum H, Sogo N, Cockcroft JR, Webb DJ. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol 1999; 34: 690-3.
42. Fan M, Kahonen M, Rontu R, et al. The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. Am Heart J 2006; 152: 538-42.
43. Nasti S, Spallarossa P, Altieri P, et al. C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucassian Italians. Dis Markers 2006; 22: 167-73.
44. Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. J Nephrol 2005; 18: 733-8.
45. Okamoto Y, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-93.
46. Yamori Y, Nagaoka A, Okamoto K. Importance of genetic factors in stroke: An evidence obtained by selective breeding of a stroke-prone and -resistant SHR. Jpn Circ J 1974; 38: 1095-100.
47. Davidson AO, Schork N, Jaques BC, et al. Blood pressure in genetically hypertensive rats: Influence of the Y chromosome. Hypertension 1995; 26:452-9.
48. Clark JS, Jeffs B, Davidson AO, et al. Quantitative trait loci in genetically hypertensive rats: possible sex specificity. Hypertension 1996; 28: 898-906.
49. Alexander MY, Brosnan MJ, Hamilton CA, et al. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc Res 1999; 43: 798-807.
50. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension - Role of the endothelium. Hypertension 1999; 33: 1353-8.
51. Fennell JP, Brosnan MJ, Frater AJ, et al. Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Ther 2002; 9: 110-7.
52. Jeffs B, Clark JS, Anderson NH, et al. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet 1997; 16: 364-7.
53. Markel P, Shu P, Ebeling C, et al. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet 1997; 17: 280-4.
54. Jeffs B, Negrin CD, Graham D, et al. Applicability of a "speed" congenic strategy to dissect blood pressure quantitative trait loci on rat chromosome 2. Hypertension 2000; 35: 179-87.
55. Nabika T, Kobayashi Y, Yamori Y. Congenic rats for hypertension: how useful are they for the hunting of hypertension genes? Clin Exp Pharmacol Physiol 2000; 27: 251-6.
56. McBride MW, Graham A Delles C, Dominiczak AF. Functional genomics in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 145-51.
57. McBride MW, Carr FJ, Graham D, et al. Microarray analysis of rat chromosome 2 congenic strains. Hypertension 2003; 41: 847-53. Erratum in: Hypertension 2003; 41: e13.
58. Aitman TJ, Glazier AM, Wallace CA, et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999; 21: 76-83.
59. He NG, Awasthi S, Singhal SS, Trent MB, Boor PJ. The role of glutathione S-transferases as a defense against reactive electrophiles in the blood vessel wall. Toxicol Appl Pharmacol 1998; 152: 83-9.
60. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
61. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999; 31: 273-300.
62. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000; 36: 142-6.
63. Pearson WR, Vorachek WR, Xu SJ, et al. Identification of classmu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 1993; 53: 220-33.
64. Patskovsky YV, Huang MQ, Takayama T, Listowsky I, Pearson WR. Distinctive structure of the human GSTM3 gene-inverted orientation relative to the mu class glutathione transferase gene cluster. Arch Biochem Biophys 1999; 361: 85-93.
65. Xu S, Wing Y, Roe B, Pearson WR. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. J Biol Chem 1998; 273: 3517-27.
66. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
67. Guy CA, Hoogendoom B, Smith SK, Coleman S, O'Donovan MC, Buckland PR. Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 2004; 14: 45-51.
68. Lilogtou T, Walters M, Maloney P, Youngson J, Field JK. A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer. Lung Cancer 2002; 37: 143-6.
69. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159-64.
70. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993; 14: 1821-4.
71. Sierra-Torres CH, Au WW, Arrastia CD, et al. Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen 2003; 41: 69-76.
72. Canbay E, Dokmetas S, Canbay EI, Sen M, Bardakci F. Higher glutathione transferase GSTM1 0/0 genotype frequency in young thyroid carcinoma patients. Curr Med Res Opin 2003; 19: 102-6.
73. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 2003; 128: 674-80.
74. Palmer CN, Doney AS, Lee SP, et al. Glutathione S-transferase M1 and P1 genotype, passive smoking, and peak expiratory flow in asthma. Pediatrics 2006; 118: 710-6.
75. Gilliland FD, Li YF, Saxon A, Diaz-Sanchez D. Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study. Lancet 2004; 363: 119-25.
76. Ivashchenko TE, Shved NIu, Kramareva NA, Ailamazian EK, Baranov VS. Analysis ofthe polymorphic alleles of genes encoding phase 1 and phase 2 detoxication enzymes in patients with endometriosis. Genetika 2003; 39: 525-9.
77. Smith CM, Kelsey KT, Wiencke JK, Leyden K, Levin S, Christiani DC. Inherited glutathione-S-transferase deficiency is a risk factor for pulmonary asbestosis. Cancer Epidemiol Biomarkers Prev 1994; 3: 471-7.
78. Hayek T, Stephens JW, Hubbart CS, et al. A common variant in the glutathione S transferase gene is associated with elevated markers of inflammation and lipid peroxidation in subjects with diabetes mellitus. Atherosclerosis 2006; 184: 404-12.
79. Iwai N, Tago N, Yasui N, et al. Genetic analysis of 22 candidate genes for hypertension in the Japanese population. J Hypertens 2004; 22: 1119-26.
80. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000; 14: 791-6.
81. Masetti S, Botto N, Manfredi S, et al. Interactive effect of the glutathione S-transferase genes and cigarette smoking on occurrence and severity of coronary artery risk. J Mol Med 2003; 81: 488-94.
82. Abu-Amero KK, Al-Boudari OM, Mohamed GH, Dzimiri N. T null and M null genotypes of the glutathione S-transferase gene are risk factor for CAD independent of smoking. BMC Med Genet 2006; 7: 38.
83. Wilson MH, Grant PJ, Kain K, Warner DP, Wild CP. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S-transferase M1. Biomarkers 2003; 8: 43-50.
84. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Glutathione S-transferase mu1 deficiency, cigarette smoking and coronary artery disease. J Cardiovasc Risk 2002; 9: 25-31.
85. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
86. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38: 1395-9.
87. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-76.
88. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16:42-7.
89. Bokoch GM, Knaus, UG. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 2003; 28: 502-8.
90. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-97.
91. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
92. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-11.
93. Zalba G, Beaumont FJ, San Jose G, et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-61.
94. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-51.
95. Itoh S, Umemoto S, Hiromoto M, et al. Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation 2002; 105: 2288-95.
96. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005; 3: 254-67.
97. Aviram M, Rosenblat M, Etzioni A, Levy R. Activation of NADPH oxidase is required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism 1996; 45: 1069-79.
98. Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J, Abe Y. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun 2001; 281: 1200-6.
99. Fortuno A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidas-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004; 22: 2169-75.
100. Romero JC, Reckelholf JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-9.
101. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2003; 284: R893-912.
102. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22: 535-42.
103. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-8.
104. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004; 313:812-7.
105. De Keulenaer GW, Chappell DC, Ishizaka, N, Nerèm RM, Alexander RW, Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res 1998; 82: 1094-101.
106. McNally JS, Davis ME, Giddens DP, et al. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothetial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 2003; 285: H2290-7.
107. Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D. Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 2001; 38: 1162-6.
108. Zalba G, Beloqui O, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25: 1452-7.
109. Fortuno A, Beloqui O, San Jose G, Moreno MU, Zalba G, Diez J. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. Kidney Int Suppl 2005: S71-5.
110. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-21.
111. Zalba G, San Jose G, Beaumont FJ, Fortuno MA, Fortuno A, Diez J. Polymorphisms and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ Res 2001; 88: 217-22.
112. Zalba G, Jose GS, Moreno MU, Fortuno A, Diez J. NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of the p22(phox) Gene in Hypertension. Antioxid Redox Signal 2005; 7:1327-36.
113. DeLeo FR, Burritt JB, Yu L, Jesaitis AJ, Dinauer MC, Nauseef WM. Processing and maturation of flavocytochrome b559 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 2000 275: 13986-93.
114. Inoue N, Kawashima, S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998; 97: 135-7.
115. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-7.
116. Moreno MU, San Jose G, Fortuño A, Beloqui O, Diez J, Zalba G. The C242T CYBA polymorphism of the NADPH oxidase is associated with Essential Hypertension. J Hypertens 2006; 24: 1299-306.
117. Schneider MP, Hilgers KF, Huang Y, et al. The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond) 2003; 105: 97-103.
118. San Jose G, Moreno MU, Olivan S, et al. Functional effect of the p22phox -930A/G polymorphism on p22pbox expression and NADPH oxidase activity in hypertension. Hypertension 2004; 44: 163-9.
119. Raijmakers MT, Roes EM, Steegers EA, Peters WH. The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia. J Hum Hypertens 2002; 16:423-5.
120. Gardemann A, Mages P, Katz N, Tillmanns H, Haberbosch W. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999; 145: 315-23.
121. Forsberg I, de Faire U, Morgeostern R. Oxidative stress, human gonetic variation, and disease. Arch Biochem Biophys 2001; 389: 84-93.
122. Friese RS, Mahboubi P, Mahapatra NR, et al. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Am J Hyperiens 2005; 18: 633-52.
123. Hingorani AD. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 2003; 5: 19-25.
124. Ukkola O, Erkkila PH, Savolainen MJ, Kesaniemi YA. Lack of association between polymorphisms of catelase, copper-zinc superoxide dismutase (SOD), extracellular SOD and andothelial nitric oxide synthase genes and macroangiopathy in patients with type 2 diabetes mellitus. J Intern Med 2001; 249: 451-9.
125. Hamanishi T, Furuta H, Kato H, et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes 2004; 53: 2455-60.
126. Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron Artery Dis 2003; 14: 149-53.
127. Forsberg L, de Faire U, Marklund SL, Andersson PM, Stegmayr B, Morgenstern R. Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. Blood Cells Mol Dis 2000; 26: 423-6.
128. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38: 153-63.
129. Laird NM, Lange C. Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet 2006; 7: 385-94.
130. Hirschhom JN, Lohmueller K, Byrne E, Hirschhom K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
131. Page GP, George V, Go RC, Page PZ, Allison DB. "Are we there yet?": deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet 2003; 73: 711-9.
132. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004; 96: 421-3.
133. van den Oord EJ, Sullivan PF. False discoveries and models for gene discovery. Trends Genet 2003; 19: 537-42.
134. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
135. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet 2004; 75: 353-62.
136. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001; 2:343-72.
137. Segre D, Deluna A, Church GM, Kishony R. Modulu epistasis in yeast metabolism. Nat Genet 2005; 37: 77-83.
138. Tong AH, Lesage G, Bader GD, et al. Global mapping of the yeast genetic interaction network. Science 2004; 303: 808-13.
139. Moore JH. A global view of epistasis. Nat Genet 2005; 37: 13-4.
140. Matsuzaki H, Dong S, Loi H, et al. Genotypiqg over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 2004; 1: 109-11.
141. Gunderson KL, Steemers FJ, Lee G, et al. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 2005; 37: 549-54.
142. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53. Errata in: N Engl J Med 2000; 342: 1376; N Engl J Med 2000;342:748.
143. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33.
144. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
145. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107: 947-53.